Results 211 to 220 of about 211,965 (305)
Cost Sharing for Preferred Branded Drugs in Medicare Part D.
Trish E, Blaylock B, Van Nuys K.
europepmc +1 more source
ABSTRACT Background Patients undergoing cancer treatment incur significant out‐of‐pocket costs attributed to both medical and non‐medical expenditure. We quantified out‐of‐pocket costs for patients receiving surgical treatment for oesophageal cancer and their financial toxicity.
Josipa Petric +6 more
wiley +1 more source
Projected Out-of-Pocket Savings of the Medicare Part D $2 Drug List Model.
Hernandez I +5 more
europepmc +1 more source
Use of Muscle Relaxants After Surgery in Traditional Medicare Part D Enrollees. [PDF]
Bongiovanni T +6 more
europepmc +1 more source
ABSTRACT Background Obesity is a major risk factor for perioperative complications following total joint arthroplasty (TJA). Bariatric surgery has been proposed to reduce these risks, but previous studies report inconsistent findings. The effect of bariatric surgery before arthroplasty remains uncertain.
Mohammad Faraz +3 more
wiley +1 more source
In this large cohort of women in Australia, a history of fertility problems was not independently associated with adverse pregnancy outcomes after adjustment. Observed risks were more likely attributable to shared underlying maternal health and lifestyle factors.
Cathryn A. Tully +4 more
wiley +1 more source
Inflation Reduction Act Provisions and Medicare Part D Out-of-Pocket Costs for Specialty Drugs.
Doshi JA, Li P, Klebanoff MJ, Lin JK.
europepmc +1 more source
Medical school ranking and provider outpatient Medicare Part D claims for antibiotics among older patients in the USA. [PDF]
Al Mohajer M +3 more
europepmc +1 more source

